二甲双胍联合复方醋酸环丙孕酮治疗青春期PCOS疗效分析

目的:探讨二甲双胍联合复方醋酸环丙孕酮(CPA)对青春期多囊卵巢综合征(PCOS)患者的临床疗效.方法:将23例青春期PCOS患者随机分为两组,A组(n=13)给予复方CPA,B组(n=10)联合给予复方CPA和二甲双胍(1 500mg/d),用药3个月后,观察治疗前后临床表现、血浆性激素水平、空腹血糖、空腹胰岛素水平的变化,以及短期对氯米芬(CC)促排卵的反应和黄体生成激素(LH)反跳率.结果:治疗3个月后,两组患者卵泡刺激素(FSH)、LH水平、IH/FSH 比值较治疗前明显降低,有显著性差异(P＞0.05),多毛、痤疮症状改善,雄激素水平无明显变化.在A组稳态模型胰岛素抵抗指数(HOMA-IR)较治疗前升高,差异有统计学意义(P＜0.05).A组8例患者(61.55%)和B组6例患者(60.00%)对CC无反应,在3个周期CC后,A组有8例患者(61.55%)和B组3例患者(30.00%)出现LH反跳,B组的LH反跳比例低于A组,但无统计学差异(P＞0.05).结论:复方CPA联合二甲双胍治疗青春期PCOS可以改善患者的临床症状,降低LH水平,降低LH反跳率,可作为青春期PCOS治疗的选择.     

复方醋酸环丙孕酮与螺内酯干预对非肥胖型多囊卵巢综合征(PCOS)内分泌代谢的影响

目的:比较复方醋酸环丙孕酮和螺内酯治疗以高雄激素血症为主要表现的非肥胖型多囊卵巢综合征(PCOS)的临床疗效和对内分泌代谢的影响。方法:按前瞻性随机对照研究方法选择以高雄激素血症为主要表现的非肥胖型PCOS患者80例,按随机化分组方案分为复方醋酸环丙孕酮(EE-CA)组和螺内酯(Sp)组,每组40例,分别口服相应的药物6个月,比较治疗前、后的体质量指数(BMI)、腰臀比(WHR)、多毛体征、痤疮程度以及卵巢体积,并测定血清卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E2)、泌乳素(PRL)、总睾酮(T)、性激素结合球蛋白(SHBG)、硫酸脱氢表雄酮(DHEAS)、空腹血糖(FPG)、空腹胰岛素(FINS)和血脂的水平,记录服药后不良反应。结果:治疗多毛EE-CA和Sp疗效接近(P>0.05);EE-CA组治疗6个月后痤疮评分下降较Sp组作用明显(P<0.05),在缩小卵巢体积方面显著优于Sp(P<0.05),降低血LH、LH/FSH、T、游离雄激素指数(FAI)、DHEAS和升高SHBG的作用较Sp组显著(P<0.05,P<0.01);EE-CA组FINS、甘油三酯(TG)和高密度脂蛋白(HDL)高于Sp组(P<0.05)。结论:本研究用于治疗以高雄激素血症为主要表现的非肥胖型PCOS的药物都是有效的;EE-CA降低高雄激素血症的效果优于Sp,但对高甘油三酯的患者使用要慎重;Sp亦有较好的降雄激素作用,且对糖、脂代谢没有显著影响。     

二甲双胍联合炔雌醇环丙孕酮在多囊卵巢综合征治疗中的应用价值

目的 探讨多囊卵巢综合征患者采用二甲双胍联合炔雌醇环丙孕酮治疗的临床效果。方法 选取60例多囊卵巢综合征患者,根据信封法分为两组,每组30例。对照组给予炔雌醇环丙孕酮治疗,研究组在对照组基础上联合二甲双胍治疗。比较两组治疗前后的性激素水平、胰岛素水平、月经规律恢复及排卵恢复情况。结果 治疗后研究组睾酮(T)、卵泡刺激素(FSH)、雌二醇(E₂)、促黄体生成素(LH)水平均低于对照组(P<0.05)。治疗后研究组空腹胰岛素(FINS)及胰岛素抵抗指数(HOMA-IR)低于对照组,胰岛素分泌指数(HOMA-β)高于对照组(P<0.05)。研究组月经规律恢复率93.33%高于对照组的73.33%,排卵恢复正常率96.67%高于对照组的80.00%(P<0.05)。结论 炔雌醇环丙孕酮联合二甲双胍能改善多囊卵巢综合征患者性激素、胰岛素水平,促进患者月经规律和排卵恢复,值得临床推广与应用。     

复方醋酸环丙孕酮和罗格列酮序贯用药对氯米芬抵抗的多囊卵巢综合征患者内分泌及生育功能的影响

目的探讨复方醋酸环丙孕酮和罗格列酮序贯用药对改善多囊卵巢综合征（PCOS）患者生育功能的临床疗效。方法30例氯米芬抵抗的PCOS胰岛素抵抗患者，口服复方醋酸环丙孕酮3个月后，罗格列酮联合氯米芬用药6个月，比较用药前后体重指数、月经周期、生殖激素水平、排卵率、妊娠率、血糖和胰岛素水平的变化。结果与用药前相比，服用复方醋酸环丙孕酮后，雄激素水平和LH／FSH值明显降低（P〈0．05），服用罗格列酮后，胰岛素抵抗指数（Homa IR）、胰岛素分泌指数（Homa β）以及β细胞功能评定指数（MBCI）均较用药前降低（P〈0．05）。结论复方醋酸环丙孕酮和罗格列酮序贯用药可有效地抑制氯米芬抵抗的PCOS患者的高雄激素血症，改善胰岛素抵抗及生育功能。     

复方醋酸环丙孕酮联合安体舒通治疗PCOS不孕的疗效观察

目的探讨复方醋酸环丙孕酮(CPA)联合安体舒通治疗PCOS不孕的治疗效果.方法将96例PCOS不孕患者随机分成两组,实验组给予复方醋酸环丙孕酮1片/d,连续用21日,待撤退性出血第5天开始下一周期治疗,同时给予安体舒通40mg,每日2次.治疗前及治疗3个周期后用化学发光免疫检测FSH、LH、E2、PRL、T.实验组给予治疗3个周期后,对照组在完成各项检查后进行促排卵治疗.结果实验组治疗后,PCOS临床症状明显改善,LH水平明显降低,LH/FSH恢复正常,T水平明显降低,服药前后比较差异有非常显著性(P＜0.01).实验组周期排卵率、单卵泡发育率、妊娠率均显著高于对照组(P＜0.01).结论复方醋酸环丙孕酮联合安体舒通治疗PCOS不孕患者,可改善患者的高雄激素征候群,使多数患者内分泌失调状态调至正常水平,提高促排卵的排卵率及临床妊娠率.     

二甲双胍联合复方醋酸环丙孕酮治疗青春期PCOS疗效分析

目的：探讨二甲双胍联合复方醋酸环丙孕酮（CPA）对青春期多囊卵巢综合征（PCOS）患者的临床疗效。方法：将23例青春期PCOS患者随机分为两组，A组（n=13）给予复方CPA，B组（n=10）联合给予复方CPA和二甲双胍（1500mg／d），用药3个月后，观察洽疗前后临床表现、血浆性激素水平、空腹血糖、空腹胰岛素水平的变化，以及短期对氯米芬（CC）促排卵的反应和黄体生成激素（LH）反跳率。结果：治疗3个月后，两组患者卵泡刺激素（FsH）、LH水平、LH／FSH比值较治疗前明显降低，有显著性差异（P〈O．05），多毛、痤疮症状改善，雄激素水平无明显变化。在A组稳态模型胰岛素抵抗指数（HOMA—IR）较治疗前升高，差异有统计学意义（P〈O．05）。A组8例患者（61．55％）和B组6例患者（60．00％）对CC无反应，在3个周期CC后，A组有8例患者（61．55％）和B组3例患者（30．00％）出现LH反跳，B组的LH反跳比例低于A组。但无统计学差异（P〉O．05）。结论：复方CPA联合二甲双胍治疗青春期PCOS可以改善患者的临床症状，降低LH水平，降低LH反跳率，可作为青春期PCOS治疗的选择。     

二甲双胍联合炔雌醇环丙孕酮片治疗多囊卵巢综合征疗效及对患者性激素和IP-10、HSP90水平的影响

目的探讨二甲双胍联合炔雌醇环丙孕酮片治疗多囊卵巢综合征(PCOS)疗效。方法选择2016年2月至2018年2月广东省佛山市第一人民医院妇产科收治的116例PCOS患者,其中对照组(58例)采用炔雌醇环丙孕酮片治疗,试验组(58例)采用二甲双胍联合炔雌醇环丙孕酮片治疗。统计两组疗效,血清性激素以及IP-10、HSP90、空腹血糖(FBG)和空腹胰岛素(FINS)水平差异。结果观察组治疗有效率高于对照组(P 0.05);治疗后观察组T、LH、IP-10、HSP90、IP-10、HSP90、FBG和FINS水平低于对照组(P 0.05);治疗后实验组患者两组患者BMI和WHR小于对照组(P 0.05)。结论二甲双胍联合炔雌醇环丙孕酮片治疗PCOS疗效显著。     

青春期不同月经方式的多囊卵巢综合征120例育龄期内分泌状态的研究

目的　探讨青春期不同月经方式的多囊卵巢综合征 (PCOS)患者在育龄期内分泌状态。方法　选择12 0例PCOS育龄妇女 ,按青春期月经方式分为三组。测定其血清性激素、胰岛素、血糖 ,并进行分析对比。结果　原发不孕的PCOS患者青春期月经异常的发生率明显高于继发不孕的PCOS患者 (P <0 0 5 )。青春期月经稀发组T及E2 显著高于继发闭经组 ,A显著高于月经规律组 (P <0 0 5 )。继发闭经组胰岛素拮抗指数和BMI显著高于月经规律组 (P <0 0 5 )。结论　在青春期表现有月经稀发和继发闭经的PCOS患者在育龄期有更严重的分泌代谢失调、并伴有较低的妊娠率。     

炔雌醇环丙孕酮联合二甲双胍治疗多囊卵巢综合征的临床效果观察

目的 观察炔雌醇环丙孕酮联合二甲双胍治疗多囊卵巢综合征(PCOS)的临床效果.方法 选取90例PCOS患者,按照随机数字表法分为研究组(采用炔雌醇环丙孕酮联合二甲双胍治疗)与对照组(采用炔雌醇环丙孕酮治疗),每组45例.比较两组治疗前后激素水平、排卵率及妊娠率.结果 治疗前,两组卵泡刺激素(FSH)、促黄体生成素(LH...     

二甲双胍联合炔雌醇环丙孕酮片治疗多囊卵巢综合征的疗效观察

目的观察二甲双胍联合炔雌醇环丙孕酮片治疗多囊卵巢综合症(PCOS)的疗效。方法选取2014年5月~2015年5月我院收治的PCOS患者92例作为研究对象,按照治疗方法将其分为对照组40例与观察组52例。对照组单用炔雌醇环丙孕酮片治疗,观察组在对照组治疗基础上联合二甲双胍治疗,并观察两组患者的疗效、性激素各指标水平及胰岛素抵抗情况。结果观察组总有效率为96.2%,明显高于对照组的65.0%;两组治疗后LH、FSH及T水平均低于治疗前,E2水平高于治疗前,且HOMA-IR、HOMA-β指数均低于治疗前,差异均有统计学意义(P0.05)。结论二甲双胍和炔雌醇环丙孕酮片联合治疗PCOS的疗效显著,值得临床推广。     

应用复方醋酸环丙孕酮治疗多囊卵巢综合征及合并耐氯Di酚不育的 …

目的 评估复方醋酸环丙孕酮（复方ＣＰＡ）治疗多囊卵巢综合征（ＰＣＯＳ）的疗效及安全性,探索葶药后改善促排卵效果的可行性。方法 ２９例ＰＣＯＳ患者「１６例为耐氯Ｄｉ酚（ＣＣ）或绝经期促性腺激素（ｈＭＧ）促排卵失败的无排卵性不育」,于自然月经或撤退性出血第５天服复方ＣＰＡ,共４～６个周期。服药前后观察临床表现、盆腔超声相、血清生殖激素、血脂水平的变化及副反应。停药后,耐ＣＣ的１２例再行ＣＣ促排卵２２个     

PCOS患者脂肪组织IRS-1、IRS-2蛋白表达及其酪氨酸磷酸化的研究

目的:研究多囊卵巢综合征(polycystic ovary syndrome,PCOS)患者脂肪组织胰岛素受体底物-1(insulin receptor substrate-1,IRS-1)及胰岛素受体底物-2(insulin recep-tor substrate-2,IRS-2)蛋白的表达及其酪氨酸磷酸化,探讨PCOS产生胰岛素抵抗(insulinresistance,IR)的分子机制。方法:用放射免疫法检测各实验组血清促黄体生成素(luteini-zing hormone,LH)、促卵泡激素(follicle stimulating hormone,FSH)、睾酮(testosterone,T)、血清空腹胰岛素(fasting insulin,FIN)的水平;用葡萄糖氧化酶法测定血浆空腹血糖(fast-ing plasma glucose,FPG);用HOMA(homeostasis model assessment,HOMA)模型计算胰岛素抵抗指数(HOMA-IR);用Western blot检测IRS-1及IRS-2蛋白的表达,应用免疫沉淀及增强化学发光法检测二者的酪氨酸磷酸化程度。结果:(1)PCOS IR组患者血清LH、LH/FSH、T、FIN及HOMA-IR均显著高于PCOS非IR组与对照组(均P(0.05);(2)PCOSIR组与PCOS非IR组及对照组相比,IRS-1蛋白表达量明显下降(P(0.05),IRS-2蛋白表达差异无统计学意义(P>0.05);(3)PCOS IR组IRS-1及IRS-2蛋白质酪氨酸磷酸化程度显著降低(均P(0.05)。结论:PCOS患者脂肪组织IRS-1蛋白表达下降,IRS-1及IRS-2蛋白质酪氨酸磷酸化程度降低,由此导致的受体后信号转导障碍可能是产生胰岛素抵抗的机制之一。     

达因-35对不同类型多囊卵巢综合征的疗效分析

目的:探讨达因-35对不同类型多囊卵巢综合征(PCOS)血清激素及窦卵泡数等的影响。方法:将138例PCOS患者按鹿特丹标准进行分型,选择同期无高雄激素血症及月经紊乱的输卵管性不孕患者78例作为对照组。测定血清生殖激素及空腹胰岛素(FINS)等水平,盆腔超声检测卵巢体积及窦卵泡计数,经达因-35治疗3个周期后观察上述指标变化,评价达因-35对不同类型PCOS的治疗效果。结果:A型[无排卵(O/A)+高雄激素(HA)+卵巢多囊(PCO)]、B型(O/A+PCO)、C型(HA+O/A)和D型(HA+PCO)分别为43例、73例、15例和7例。A型、C型和D型总睾酮(TT)和硫酸脱氢表雄酮(DHEAS)水平高于对照组,各型LH、LH/FSH、FINS及胰岛素评价指数(HOMA-IR)高于对照组,差异均有统计学意义(P0.05)。A型、B型和D型窦卵泡数多于C型及对照组,差异有统计学意义(P0.05)。达因-35治疗3个周期后:A型、C型和D型血清TT降低,差异有统计学意义(P0.05);DHEAS水平有所降低,但差异无统计学意义(P0.05);各型PCOS血清LH和LH/FSH下降,窦卵泡数减少,差异均有统计学意义(P0.01)。结论:华中地区PCOS临床表现以A型和B型多见,达因-35治疗3个周期可明显降低不同类型血清雄激素水平、血清LH水平和LH/FSH比值,减少窦卵泡数。     

Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: the effect of ethinyl estradiol–cyproterone acetate treatment

The role of melatonin in human reproduction is still unknown. Data obtained in patients with hypogonadism and precocious puberty suggest that melatonin and the reproductive hormones are interrelated.The aim of this study was to determine melatonin production in hyperandrogenic women. We studied 12 women with polycystic ovary syndrome (PCOS) and 10 women with idiopathic hirsutism (IH). Patients were treated with cyproterone acetate–ethinyl estradiol (Diane 35) for 4 months. Fasting blood samples for the determination of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone and dehydroepiandrosterone sulfate (DHEAS) and 24-h urine collections for the determination of 6-sulfatoxymelatonin (αMT6s) excretion were obtained from all patients at baseline and after 4 months of treatment. The results were compared with those obtained in 15 control women. At baseline, women with PCOS had significantly higher LH and testosterone levels than those with IH and controls. Their αMT6s values (52.6?±?20.3?µg/24?h) were significantly higher than the values in women with IH (34.3?±?7.1) and controls (30.5?±?6.5) (p?<?0.001). Diane 35 treatment significantly decreased LH, FSH, testosterone and αMT6s values in PCOS (28.0?±?13.9?µg/24?h) (p?<?0.0001). These results indicate that women with PCOS have increased melatonin production. The normalization of αMT6s and testosterone values during Diane 35 treatment suggests that sex steroids modulate melatonin secretion in these patients either directly or through the suppression of gonadotropin.     

孕三烯酮对子宫内膜异位症患者脂代谢及骨密度的影响

目的　观察孕三烯酮对子宫内膜异位症患者脂代谢、性激素水平及骨密度的影响。方法　选择经腹腔镜或开腹手术确诊为子宫内膜异位症的患者 56例,年龄 20 ~45岁,以 40岁为界限分为Ⅰ组 20~39岁(30例),Ⅱ组 40~45岁(26例)。于术后 1周开始口服孕三烯酮,每周 2次,每次 2 5mg,连服 6个月,分别于服药前、服药 6个月时、停药 6个月时测定血清胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白 胆固醇(HDL-C)、低度脂蛋白 胆固醇 (LDL C)、载脂蛋白A1 (ApoA1 )、载脂蛋白B(ApoB)、卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇水平及骨密度。结果　服药 6个月时,血清HDL C、ApoA1,Ⅰ组为(1.13±0.26)mmol/L、( 0.91±0.76)g/L;Ⅱ组为(0.95±0.24)mmol/L、(0.92±0.16)g/L;血清LDL-C、ApoB,Ⅰ组为 ( 2.6±0.8 )mmol/l、( 1.28±0.16 )g/L;Ⅱ组为 ( 3. 7±1.1)mmol/L、(1.47±0.44)g/L;服药 6个月时雌二醇及骨密度也显著下降,而TG、TC、FSH、LH水平无明显变化。停药 6个月时,上述各指标均能恢复至服药前水平,骨密度回升,但未能完全达到服药前水平,但停药后 1年,骨密度基本接近服药前水平。结论　孕三烯酮治疗子宫内膜异位症可降低雌二醇水平和骨密度,对血脂代谢有不利的影响,故不宜长期使用;停药 6个月后各指标基本恢复。     

Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia?

OBJECTIVE: To assess gonadotropin alterations in adult-onset congenital adrenal hyperplasia (CAH) and to compare these findings with those of patients with polycystic ovary syndrome (PCOS) in an effort to better understand the pathophysiology of these abnormalities. DESIGN: Prospective study of 9 newly diagnosed patients with CAH, 10 with PCOS, and 10 ovulatory controls. INTERVENTIONS: Baseline measurements of serum androgens, progestins, estradiol (E2), estrone (E1), unbound E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Serum LH and FSH were measured after intravenous gonadotropin-releasing hormone (GnRH) and in 15-minute blood samples for 6 hours to determine LH pulsatility. RESULTS: Serum androgens were elevated but comparable in the two patient groups. Serum LH was also elevated (P less than 0.05) but was higher in PCOS than CAH. Serum LH:FSH ratios were similar as were the responses to GnRH. Serum E1 was elevated only in PCOS, but unbound E2 was elevated to the same degree in both PCOS and CAH (P less than 0.05). Patients with PCOS had a decreased LH interpulse interval compared with controls and CAH (P less than 0.05), but LH pulse amplitude was increased in both PCOS and CAH (P less than 0.05). Serum E2 and unbound E2 correlated significantly with LH (P less than 0.05), LH responses to GnRH as well as to LH pulse amplitude in CAH (P less than 0.05). The LH interpulse interval did not correlate with estrogen in any group. None of the LH parameters correlated with serum progestin levels in CAH. CONCLUSIONS: The gonadotropin abnormalities of CAH appear to be intermediate between those of controls and PCOS. Although elevated estrogen may explain these abnormalities in CAH, additional factors may be operative in PCOS.     

Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: the effect of ethinyl estradiol-cyproterone acetate treatment.

The role of melatonin in human reproduction is still unknown. Data obtained in patients with hypogonadism and precocious puberty suggest that melatonin and the reproductive hormones are interrelated. The aim of this study was to determine melatonin production in hyperandrogenic women. We studied 12 women with polycystic ovary syndrome (PCOS) and 10 women with idiopathic hirsutism (IH). Patients were treated with cyproterone acetate-ethinyl estradiol (Diane 35) for 4 months. Fasting blood samples for the determination of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone and dehydroepiandrosterone sulfate (DHEAS) and 24-h urine collections for the determination of 6-sulfatoxymelatonin (alpha MT6s) excretion were obtained from all patients at baseline and after 4 months of treatment. The results were compared with those obtained in 15 control women. At baseline, women with PCOS had significantly higher LH and testosterone levels than those with IH and controls. Their alpha MT6s values (52.6 +/- 20.3 micrograms/24 h) were significantly higher than the values in women with IH (34.3 +/- 7.1) and controls (30.5 +/- 6.5) (p < 0.001). Diane 35 treatment significantly decreased LH, FSH, testosterone and alpha MT6a values in PCOS (28.0 +/- 13.9 micrograms/24 h) (p < 0.0001). These results indicate that women with PCOS have increased melatonin production. The normalization of alpha MT6s and testosterone values during Diane 35 treatment suggests that sex steroids modulate melatonin secretion in these patients either directly or through the suppression of gonadotropin.     

Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical,endocrine and metabolic factors in women with polycystic ovary syndrome

Background. Polycystic ovary syndrome (PCOS) is a major endocrine abnormality that affects women of reproductive age. Oral contraceptive pills are usually the first choice of treatment for PCOS when fertility is not desired. Metformin, an insulin-sensitizing drug, has been shown to improve such metabolic abnormality.

Aim. To compare the effects of a contraceptive pill in combination with metformin on the clinical, endocrine and metabolic parameters in obese and non-obese patients with PCOS.

Methods. Sixty PCOS patients (25 obese, 35 non-obese) were enrolled in this prospective clinical study. PCOS was defined according to the Rotterdam criteria. Patients were randomized to oral treatment with Diane35® (35 μg ethinyl estradiol plus 2 mg cyproterone acetate), metformin or a combination of Diane35/metformin for 3 months. Body mass index (BMI), waist-to-hip ratio (WHR), Ferriman–Gallwey (FG) score, leuteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, fasting insulin and glucose/insulin ratio were measured at baseline and at the end of treatment.

Results. Diane35 resulted in a higher reduction of FG score in both obese and non-obese PCOS patients compared with metformin. Menstrual regularity was restored in all PCOS patients treated with Diane35 compared with only 28% of those receiving metformin. Metformin significantly decreased BMI and WHR in obese patients (p < 0.05). Testosterone levels decreased in all three groups. LH levels and LH/FSH ratio decreased with Diane35 and Diane35/metformin in both obese and non-obese patients. Metformin significantly decreased fasting insulin concentrations (p < 0.05 and p < 0.01) and increased the insulin sensitivity (p < 0.05) in both obese and non-obese PCOS patients, while no significant changes were observed in the Diane35 group. In addition, insulin levels also decreased (p < 0.05) in the Diane35/metformin group.

Conclusions. Our data show that a combination of metformin and contraceptive pill may be more effective in suppressing the hyperandrogenemia of obese and non-obese PCOS patients than metformin alone and may reduce insulin levels more than contraceptive pill alone. Hence, combined treatment may become a more effective therapeutic option for PCOS.     

Do basal inhibin A and inhibin B levels have value in the diagnosis of polycystic ovary syndrome?

In the present study we aimed to investigate whether basal inhibin A and B levels in women with polycystic ovary syndrome (PCOS) would be used in diagnosis of the condition. Forty women with PCOS and 40 women with normal cycles (control group) were evaluated. There was no statistically significant difference in mean age and mean body mass index between the two groups (p > 0.05). Serum levels of inhibin A and B, follicle-stimulating hormone (FSH), luteinizing hormone and total testosterone, and total ovarian volume, were determined in the PCOS group and the control group on day 3. In the PCOS group, total follicle number was obtained by counting follicles of diameter > or =2 mm in both ovaries. Results were evaluated using Student's t test, Pearson correlation and regression tests. There was no significant difference in mean basal inhibin A or inhibin B levels between the two groups. Basal inhibin B levels showed a statistically significant negative correlation with basal FSH levels and a positive correlation with total follicle number in the PCOS group (p < 0.05 and p < 0.01, respectively). We conclude that basal inhibin A or B levels cannot be used in the diagnosis of PCOS.     

血清抑制素B水平预测卵巢储备功能的临床价值

目的:探讨血清基础抑制素B水平与卵巢储备功能的关系及其临床价值。方法:将158例观察对象分为3组,卵巢早衰(POF)组73例,卵巢储备功能下降(DOS)组55例,卵巢功能正常组30例,分别观测其血清基础抑制素B(INHB)、雌二醇(E2)、促卵泡素(FSH)、卵巢基质血流阻力指数(RI)、窦卵泡计数(OVF)、卵巢直径(OVD)、症状积分值。结果:INHB水平在POF组及DOS组与正常组相比均有极显著性差异(P<0.001),POF组与DOS组相比也有显著性差异(P<0.05),且POF组相似文献